Alnylam partners with Viz.ai and American Heart Association on ATTR-CM care
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
March 24, 2026 7:30 AM EDTEfforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM
Alnylam to Host TTR Investor Webinar Today at 9:30 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and... More
